Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHDQZD)

Drug Name
Fezolinetant Drug Info
Synonyms
Fezolinetant; 1629229-37-3; ESN364; ESN-364; VEOZAH; 83VNE45KXX; Fezolinetant [USAN]; A2693; AS3472693-00; UNII-83VNE45KXX; ES-256364; (R)-(4-fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; CHEMBL3608680; A-2693; AS-3472693-00; (4-fluorophenyl)-[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone; Methanone, ((8R)-5,6-dihydro-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-1,2,4-triazolo(4,3-a)pyrazin-7(8H)-yl)(4-fluorophenyl)-; compound 3 (PMID:26191358); compound 3 [PMID:26191358]; (4-FLUOROPHENYL)((8R)-5,6-DIHYDRO-8-METHYL-3-(3-METHYL-1,2,4-THIADIAZOL-5-YL)-(1,2,4)TRIAZOLO(4,3-A)PYRAZIN-7(8H)-YL)METHANONE; fezolinetantum; FEZOLINETANT [INN]; FEZOLINETANT [WHO-DD]; SCHEMBL16114810; GTPL10422; ESN-364ESN-364; DTXSID601103615; EX-A6226; ?ESN-364?; BDBM50112244; WHO 10205; AKOS040741724; CS-7952; AC-36697; HY-19632; MS-25636; D87169; Q27269455; ((8R)-5,6-DIHYDRO-8-METHYL-3-(3-METHYL-1,2,4-THIADIAZOL-5-YL)-1,2,4-TRIAZOLO(4,3-A)PYRAZIN-7(8H)-YL)(4-FLUOROPHENYL)METHANONE; (4-FLUOROPHENYL)((8R)-8-METHYL-3-(3-METHYL-1,2,4- THIADIAZOL-5-YL)-5,6-DIHYDRO-1,2,4-TRIAZOLO(4,3-A)PYRAZIN- 7(8H)-YL)METHANONE; (4-FLUOROPHENYL)((8R)-8-METHYL-3-(3-METHYL-1,2,4-THIADIAZOL-5-YL)-5,6-DIHYDRO-1,2,4-TRIAZOLO(4,3-A)PYRAZIN-7(8H)-YL)METHANONE
Indication
Disease Entry ICD 11 Status REF
Hot flushes GA30 Approved [1]
Cross-matching ID
PubChem CID
117604931
TTD Drug ID
DMHDQZD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Neuromedin-K receptor (TACR3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Elinzanetant DMC6EFI Hot flushes GA30 Phase 3 [3]
Senktide DMOH8LD Epilepsy 8A60-8A68 Phase 2 [4]
AZD2624 DMZLGQV Multiple sclerosis 8A40 Phase 2 [5]
Talnetant DMQKZDT Schizophrenia 6A20 Phase 2 [6]
GSK1144814 DMK3S9J Alcohol dependence 6C40.2 Phase 1 [7]
Osanetant DMMT4PB Schizoaffective disorder 6A21 Discontinued in Phase 2b [6]
CS-003 DM1AEVT Chronic obstructive pulmonary disease CA22 Discontinued in Phase 2 [8]
SSR-146977 DMR9JA8 Psychotic disorder 6A20-6A25 Discontinued in Phase 1 [9]
SB222200 DM6X0PZ Schizoaffective disorder 6A21 Preclinical [10]
neurokinin A DM9UXRP Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuromedin-K receptor (TACR3) TTBPGLU NK3R_HUMAN Antagonist [2]

References

1 FDA Approved Drug Products from FDA Official Website.
2 Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023 Apr 1;401(10382):1091-1102.
3 Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234.
4 Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study. Br J Pharmacol. 2003 Feb;138(4):554-63.
5 The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.J Clin Psychopharmacol.2014 Apr;34(2):199-204.
6 Pharmacological characterization of senktide-induced tail whips. Neuropharmacology. 2010 Jan;58(1):259-67.
7 Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39.
8 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
9 Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can J Physiol Pharmacol. 2002 May;80(5):482-8.
10 Evidence for mediation of nociception by injection of the NK-3 receptor agonist, senktide, into the dorsal periaqueductal gray of rats. Psychopharmacology (Berl). 2009 May;204(1):13-24.
11 Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor. Eur J Pharmacol. 2001 Feb 16;413(2-3):143-50.